Amanote Research
Register
Sign In
Editorial: Not Yet Time for Universal Susceptibility-Guided First-Line Helicobacter Pylori Treatment-Authors' Reply
Alimentary Pharmacology and Therapeutics
- United Kingdom
doi 10.1111/apt.15373
Full Text
Open PDF
Abstract
Available in
full text
Categories
Hepatology
Pharmacology
Gastroenterology
Date
July 17, 2019
Authors
Hong Lu
David Y. Graham
Publisher
Wiley
Related search
Editorial: Not Yet Time for Universal Susceptibility-Guided First-Line Helicobacter Pylori Treatment
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Editorial: Helicobacter Pylori Resistance and Sequential Therapy-Authors’ Reply
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Editorial: Population-Based Testing for Helicobacter Pylori in Western Countries. Authors' Reply
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Editorial: Faecal Microbiota Transplantation for Ulcerative Colitis-Not Quite There Yet? Authors’ Reply
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Eradicating Helicobacter Pylori in Patients With Duodenal Ulcer: Authors' Reply
BMJ
Different Treatment Choice for First-Line Treatment of Helicobacter Pylori in an Area With a High Antibiotic Resistance
Turkish Journal of Gastroenterology
Gastroenterology
Efficacy of Potassium-Competitive Acid Blocker vs Proton Pump Inhibitor as First-Line and Second-Line Treatment for Helicobacter Pylori Eradication
Open Journal of Gastroenterology and Hepatology
Adding Bismuth to Rabeprazole-Based First-Line Triple Therapy Does Not Improve the Eradication of Helicobacter Pylori
Gastroenterology Research and Practice
Hepatology
Gastroenterology
Clinical Efficacy of Gemifloxacin-Containing Triple Therapy for First-Line Treatment of Helicobacter Pylori Infection: A Pilot Study
The Korean Journal of Helicobacter and Upper Gastrointestinal Research
